In line with FDA guidance that clinicians monitor for new or worsening depression, suicidal thoughts, or unusual changes in mood during GLP-1 RA treatment [46], brief psychological screening should be incorporated at baseline and repeated at intervals during treatment at weeks 6, 12, and 24, and then at least every six months
Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions
The medication can reduce appetite and increase the feeling of fullness, which can contribute to reduced calorie intake and support weight loss
Over time, sticking to new routines can be challenging, and occasional slip-ups are normal
This study was prior to the use of GLP-1 drugs for obesity, so these findings are applicable to people with diabetes